Skip to main
TTRX

TTRX Stock Forecast & Price Target

TTRX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Turn Therapeutics is a clinical-stage biotechnology company that has developed a proprietary platform technology called PermaFusion designed to enhance drug performance for the treatment of inflammatory skin diseases. Their lead product, GX-03, is being studied for moderate-to-severe eczema and has shown promising results in preclinical and real-world studies. With a strong focus on expanding their platform into other dermatological indications, coupled with a newly announced loan agreement that provides much-needed capital, Turn Therapeutics is poised for growth and success in the future.

Bears say

Turn Therapeutics is heavily reliant on its proprietary PermaFusion platform technology and its lead program, GX-03, which is currently being evaluated in a clinical study for moderate-to-severe eczema. While the company has secured a potential source of funding through a capital commitment, it is not guaranteed and comes with potential future dilution. Additionally, the lack of transparency in the company's patent portfolio makes it difficult to fully assess the strength of its intellectual property and potential for competitors to develop similar solutions.

TTRX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Turn Therapeutics Inc (TTRX) Forecast

Analysts have given TTRX a Strong Buy based on their latest research and market trends.

According to 1 analysts, TTRX has a Strong Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Turn Therapeutics Inc (TTRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.